THE IMPACT OF TEN YEARS OF IVERMECTIN MASS DRUG ADMINISTRATION ON THE LEVEL OF ENDEMICITY AND INTENSITY OF ONCHOCERCA VOLVULUS INFECTION IN THE AOWIN DISTRICT OF GHANA

ABSTRACT
Ivermectin remains the only safe drug for the control and treatment of onchocercisis in endemic areas. Despite some reports on its sub-optimal response in some parts of Ghana, long term treatment has shown that it can eliminate the infection and interrupt transmission in Africa. Taking into account the feasibility of elimination of onchocerciasis infection and transmission interruption with ivermectin mass treatment alone, Joint Action Forum (JAF), and the governing body of African Programme for Onchocerciasis Control in 2011, has reaffirmed its endorsement for the Programme to pursue the elimination of onchocerciasis in Africa. Aowin district of the Western Region of Ghana is meso-endemic for onchocerciasis infection and had received ivermectin mass drug treatment for 10 years. This study was undertaken to assess the impact of 10 years of mass drug administration with ivermectin on the level of endemicity and intensity of O. volvulus infection in Aowin district following the claim made by the District Health Directorate that onchocerciasis transmission and infection had been eliminated in the district. A cross sectional survey was conducted in 20 endemic communities situated along rivers in the district. In all, 1,698 volunteers took part in the study. They were examined by palpation for onchocercal nodules or onchodermatitis. Of the 1,698 volunteers examined, 300 who were positive for palpable nodules or onchodermatitis were skin-snipped for microfilarial load assessment. Community microfilarial load (CMFL) for each of the studied community was also determined. Onchocercal nodules and microfilarial prevalence were used to measure the level of endemicity. The intensity of infection was measured using CMFL, a reference index used by the Onchocerciasis Control Programme. The results indicated that, 298 (17.6%) out of the 1,698 examined had palpable nodules. A significant difference was observed (p=0.0001) in the nodule prevalence between males and females. Out of the 300 skin snipped, 173 (57.7%) were microfilarial-positive. The microfilarial prevalence and community microfilarial load in the study communities ranged from 8.3-88.9% and 1.0-5.2mf/mg respectively. The overall nodule and microfilarial prevalence recorded suggest strong evidence of on-going transmission of onchocerciasis despite 10 years of annual mass treatment. Halting ivermectin treatment in the district is not recommended as it might risk recrudescence of transmission.


CHAPTER ONE
INTRODUCTION
1.1: Background
Human onchocerciasis is a debilitating disease affecting about 37 million people in the world (Basáñez et al., 2006). About 500,000 people suffer from visual impairment and 270,000 have gone blind (WHO, 1995). It is also an important cause of severe dermatitis and musculoskeletal pains (WHO, 1995).

Onchocerca volvulus is the causative agent responsible for onchocerciasis (river blindness) and the various dermatological manifestations (Hoerauf et al., 2011). The infections are primarily restricted to Africa with about 96% cases mostly in the Western sub-Saharan region (Basáñez et al., 2006; WHO, 2011). O. volvulus is transmitted by Simulium damnosum, particularly S. damnosum sensu lato (s.l.) is the major species in Africa (Crosskey, 1990; Crosskey and Howard, 2004). Humans are the only known natural reservoirs (Udall, 2007). The third stage filarial larvae, L3, which is the infective larval stage are introduced by the black fly into the human host when it feeds on a blood meal, and the life cycle is completed when adult worms, residing in the nodules produce microfilariae (mf) that move throughout the dermis of the host are taken up by the black fly (Taylor et al., 2010). Simulium flies reproduce in rapidly flowing streams and rivers and the prevalence of infection and disease in a community depends upon how the community is close to the riverine breeding site of the black flies with communities adjacent to rivers serving as the highest burden of infection and disease (Taylor et al., 2010).

Onchocerciasis prevalence is highest among the age population between 20-30 years (Hailu et al., 2002; Little et al., 2004a). Men compared to female generally have higher disease prevalence possibly because of their high exposure to the bites of the black flies during farming and fishing activities. Prevalence is lowest in children under 10 years as children have less exposure to the bite of the Simulium flies whose biting activities are greatest in the morning (Hailu et al., 2002; Little et al., 2004a).

Adult filarial worms present in the nodules beneath the skin of the infected host can survive up to 14 years (Plaisier et al., 1990; Winnen et al., 2002). During this period, millions of microfilariae are produced and released into the skin of the infected individuals. The presence of these microfilariae in the skin of the infected individuals is responsible for the main clinical complications due to inflammatory reactions to the macrofilariae in the dermis and in the eyes (WHO, 1995).

The disease is a chronic, multisystemic one that leads to severe itching, blindness, skin lesions, epilepsy as a result of heavy infection, and reduced life expectancy among sighted individuals with high microfilarial (WHO, 1995). Some other consequences of infection with O. volvulus includes disability leading to significant morbidity, social ostracism, reduced work and abandonment of fertile river valleys causing reduction in agricultural output among the disease affected populations (Prost, 1986; Vlassoff et al., 2000; Boussinesq et al., 2002; Pion et al., 2002; Little et al., 2004b;). Annually, Onchocerciasis causes approximately 1.5 million healthy life-years lost as a result of impairment and mortality (Evans, 1995; Oladepo et al., 1997; Remme, 2004; Remme et al., 2006). Over half of this result from dermal diseases that have negative impact on income generating capacity, health and socio-economics of those that are affected and their dependents. (Evans, 1995; Oladepo et al., 1997; Remme, 2004; Remme et al., 2006).

Onchocerciasis is a serious public health issue because of the detrimental and devastating effects of the disease to both human and economic development (WHO, 1997). Over the past decades, governments, policy and decision makers in the world community have continuously made efforts to control and eliminate this infectious disease. In the year 1975, the World Health Organization (WHO) launched the Onchocerciasis Control Programme (OCP) of West Africa. The aim of the programme was to eradicate onchocerciasis as a disease of public-health importance from the savana areas of 11 West African countries including Ghana (WHO, 1997). The core activities of the programme included aerial larvicide spraying of rapidly flowing streams and rivers to control the multiplication of the Simulium flies and treating infected individuals with Diethylcarbamazine (DEC) that can kill microfilariae (WHO, 1997). However, DEC treatment of the infected individuals led to severe adverse effects and therefore was not considered safe for mass drug administration (Hawking, 1979).

Onchocerciasis control under the umbrella of Onchocerciasis Control Programme in West Africa (OCP) in the 11 West African countries achieved some significant successes. By the end of the programme in 2002, it covered 1,200,000 square kilometres, protected 30 million people that were at risk of the infection and prevented 600,000 people from blindness making 25 million hectares of land safe for relocation (Hopkins, 2005). It has reduced the problem of millions of the world’s poorest people (Harlem, 2002; Hopkins, 2005).

The efforts of various governments and policy makers to control and eliminate onchocerciasis as a public health burden currently rely on mass drug administration of ivermectin under the following programme; African Programme for Onchocerciasis Control (APOC), the former Onchocerciasis Control Programme (OCP) and Onchocerciasis Elimination Program for the Americas (OEPA) (Sturchio, 2001). The drug ivermectin or Mectizan® was donated by Merck & Co, in 1987.

Ivermectin was registered in 1987 for human use to treat onchocerciasis and later lymphatic filariasis (Thylefors and Lawrence, 2008; Ottesen et al., 2008). To date (2016), it continues to be the only safe drug for mass treatment of onchocercisis (Cupp et al., 2011). National control programmes in the former OCP and the WHO African Programme for Onchocerciasis Control (APOC) provide ivermectin treatment periodically using community-based volunteers (Amazigo et al., 2002) to reduce and possibly eliminate the infection where feasible. The recommended dose is 150 μg/kg body weight per annum or three times in a year and has effect on the microfilariae in the skin and the eyes (Enk, 2006; Canga et al., 2008). The drug is able to reduce levels of microfilariae in the skin and the eye and maintain it for about 9-12 months. (Greene et al., 1985; Lariviere et al., 1985; Awadzi et al., 1985; Diallo et al., 1986; White et al., 1987). Reduction of microfilarial density in the skin can significantly reduce parasite transmission but transmission cannot be interrupted after the initial few years of administration of ivermectin (Remme, 2004; Ndyomugyenyi et al., 2004). The drug also has advantageous effect on symptoms and clinical presentations of the disease. The drug relieves the intense itching from the infection and progression towards blindness except in very advanced cases. However, ivermectin does not kill adult worms directly, but hinders the release of microfilariae from the adult female worm just after the initial dose (Cupp et al., 2004; Duke, 2005). This effect can last up to a period of one year after treatment leading to degeneration of intra-uterine microfilariae and multiple treatments with the drug may increase mortality of adult worms (Cupp et al., 2004; Duke, 2005). Multiple doses of the drug have been shown to also have effect on the development of the embryo of the worms and also cause progressive restitution of the cellular anti-filarial immune response (Schulz-Key et al., 1992).

Due to the safety profile of the drug, it has been extensively used in mass drug administration since the mid-1990 and it is the WHO recommended approach for the control of onchocerciasis (WHO, 2006). As the drug has limited effect on the adult onchocercal worms, it means that persistent treatment is required in order to repress the manifestations of the infection over time (WHO, 2006). While early computer models estimated 25 years treatment to interrupt transmission, recent evidence has proposed that 5 to 15 years of ivermectin mass treatment might interrupt transmission depending on the treatment method and the pre-control endemicity level (Winnen et al., 2002; Cupp and Cupp, 2007).

Within the past 29 years of Mass Drug Administration (MDA) using ivermectin, a billion treatments have so far been administered and currently, Mectizan Donation Program (MDP) approves an average of 140 million treatments for onchocerciasis and lymphatic filariasis per year (MDP, 2016). Treatment of onchocerciasis using ivermectin mass drug administration has brought significant reduction in the transmission of the disease in the endemic areas (WHO, 2012). By mid-2012, bi-annual mass treatments with ivermectin had eliminated or interrupted transmission of the disease in 10 onchocerciasis foci in the Americas (WHO, 2012).

Many communities in Africa and Latin America have also benefitted from the infrastructure and distribution systems that were developed for the onchocerciasis control and elimination programmes. The successful nature of these ivermectin-based programmes worldwide created a model for health care. Its successful policies and plans have proven the possibility of putting forth activities and efforts to target other diseases that are chronic in poor and remote localities of the world to effect improvements in productivity, morbidity and long-term mortality (Hotez et al., 2007).

For more Clinical Microbiology Projects Click here
===================================================================
Item Type: Ghanaian Postgraduate Material  |  Attribute: 106 pages  |  Chapters: 1-5
Format: MS Word  |  Price: GH50  |  Delivery: Within 30Mins.
===================================================================

Share:

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Search for your topic here

See full list of Project Topics under your Department Here!

Featured Post

HOW TO WRITE A RESEARCH HYPOTHESIS

A hypothesis is a description of a pattern in nature or an explanation about some real-world phenomenon that can be tested through observ...

Popular Posts